VIR Vir Bio: Company Short-Term Debts

Public company logo of Vir Biotechnology, Inc. (VIR)

The price indicator on the Vir Biotechnology, Inc. (VIR) chart reflects the dynamics of a company attracting leading immunologists for the therapy of dangerous viruses, where the metric stands at 0.00. Financial stability is based on colossal cash reserves, which offset funding deficits during active R&D development. Operational activities rely on air freight with strict temperature control for the global distribution of finished antibodies.

Vir Biotechnology Inc (VIR) - Company Short-Term Loans and Borrowings from 07/04/2022 to 10/30/2026

Metric breakdowns and analytics for Vir Corp (VIR)

- current quotes and average value forecast:
Price Chart Vir Biotechnology|VIR - Consensus Target
- company stock capitalization data:
Market Capitalization Vir Biotechnology, Inc.|VIR - Enterprise Value
- business book valuation details:
Accounting Value per Share Vir Biotechnology|VIR - Accounting Value of Company|Market Cap to Net Assets Ratio vir.bio|VIR - Aggregate Company Assets
- debt level and financial liquidity data:
Total Debt to Capital Vir Biotechnology, Inc.|VIR - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Vir Biotechnology, Inc.|VIR - Aggregate Debt Obligations|Debt to Book Value Vir Biotechnology, Inc.|VIR - Company Long-Term Debts|Company Short-Term Debt Vir Biotechnology|Quick Liquidity Indicator vir.bio
- earnings and valuation multiples indicators:
VIR - Company Net Income
General company analysis:Vir Biotechnology - VIR
Manufactured products of Vir Biotechnology, Inc.

This indicator measures the issuer's total liabilities with a maturity of up to one year. The dynamics of the company's short-term debt allow for an assessment of current liquidity and the risk of cash flow gaps. The metric aggregates all current loans and borrowings, reflecting the pressure on working capital. For Vir Biotechnology, Inc. (VIR), controlling these obligations is critical while pivoting its pipeline from COVID-19 drugs to hepatitis therapies. Debt optimization ensures financial stability during a period of deep business diversification.

Competitors of Vir Biotechnology, Inc. (VIR)

GILD - Company Short-Term Debt|cidara.com (CDTX) - Company Current Liabilities|NVAX: Company Short-Term Debts|CureVac Pharma (CVAC) - Company Short-Term Debts|Company Current Liabilities VALN|SIGA: Company Short-Term Loans and Borrowings|Company Current Liabilities EBS (Emergent BioSolutions Inc.)|Company Short-Term Debt AVIR (Atea Pharma)|Company Short-Term Debts IVVD (Invivyd)|Short-Term Debt Volume Enanta Pharmaceuticals, Inc (ENTA)|INO - Company Short-Term Debt|Company Short-Term Loans and Borrowings HLVX (hillevax.com)|KLRS (Kalaris Therapeutics) - Company Current Liabilities|Dyadic International, Inc. (DYAI) - Company Short-Term Debts|Company Short-Term Debt NanoViricides Inc.|Talphera Corporation (TLPH) - Short-Term Debt Volume|Company Current Liabilities COCP (Cocrystal Pharma, Inc.)|Company Short-Term Debt TRAW (trawspharma.com)|Company Short-Term Debts DWTX (Dogwood Therapeutics)|Short-Term Debt Volume Qualigen Therapeutics Inc (QLGN)|ALVR - Company Short-Term Debt|Company Short-Term Loans and Borrowings VBIV (VBI Vaccines Inc.)|VIRI (virios.com) - Company Current Liabilities|Vaxart - Company Short-Term Loans and Borrowings